Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claudia dos Santos Mermelstein"'
Autor:
Gisele Barbosa, Luis Gabriel Valdivieso Gelves, Caroline Marques Xavier Costa, Lucas Silva Franco, João Alberto Lins de Lima, Cristiane Aparecida-Silva, John Douglas Teixeira, Claudia dos Santos Mermelstein, Eliezer J. Barreiro, Lidia Moreira Lima
Publikováno v:
Pharmaceuticals, Vol 15, Iss 8, p 913 (2022)
Combretastatin A-4 (CA-4, 1) is an antimicrotubule agent used as a prototype for the design of several synthetic analogues with anti-tubulin activity, such as LASSBio-1586 (2). A series of branched and unbranched homologs of the lead-compound 2, and
Externí odkaz:
https://doaj.org/article/8fe7ce838ac14269812abfc874254714
Publikováno v:
Anais da Academia Brasileira de Ciências, Vol 72, Iss 3, Pp 341-351 (2000)
The electric eel Electrophorus electricus is a fresh water teleost showing an electrogenic tissue that produces electric discharges. This electrogenic tissue is distributed in three well-defined electric organs which may be found symmetrically along
Externí odkaz:
https://doaj.org/article/71545afed443438c811ff46606bdccdd
Autor:
Claudia Dos Santos MERMELSTEIN, Marlene BENCHIMOL, Marilia TAFFAREL, Maria Cristina, Rocha CORDEIRO, Carlos CHAGAS, Vivaldo MOURA NETO
Publikováno v:
Archives of Histology and Cytology. 60:445-452
The electrocyte of the electric organ of the electric eel, Electrophorus electricus, L was investigated by light and electron microscopy as well as immuno-electron microscopy, in order to clarify the fine structures and distribution of cytoskeleton f
Autor:
Ramon Guerra de Oliveira, Fabiana Sélos Guerra, Cláudia dos Santos Mermelstein, Patrícia Dias Fernandes, Isadora Tairinne de Sena Bastos, Fanny Nascimento Costa, Regina Cely Rodrigues Barroso, Fabio Furlan Ferreira, Carlos Alberto Manssour Fraga
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 33, Iss 1, Pp 1181-1193 (2018)
In this study, we synthesized a new congener series of N-sulphonylhydrazones designed as candidate ROCK inhibitors using the molecular hybridization of the clinically approved drug fasudil (1) and the IKK-β inhibitor LASSBio-1524 (2). Among the synt
Externí odkaz:
https://doaj.org/article/d73b148125364d7da3c2636102c54a57